Direct comparison
510(k) clearance vs PMA
510(k) clearance and Premarket Approval (PMA) are the two principal FDA pathways for medical devices, differing in evidence standard, device risk class and whether the FDA "clears" or "approves" the device.
The step most authors miss
Doing CRediT right? Don’t stop at the statement.
A CRediT statement credits you inside one paper. The recognition CRediT was built for happens when those roles are tied to you, persistently. Sign in with your ORCID — free — and claim your CRediT contributions on casrai.org, the home of the standard. They become a verified, portable part of your identity, not a line that disappears into one PDF.
Free: claim your contributions, then export a journal-ready CRediT statement, schema.org structured data, JATS XML, CSV or BibTeX — and preview your public profile. A membership publishes that profile publicly and verifies the journals you serve.
Side-by-side comparison
| Dimension | 510(k) clearance | PMA approval |
|---|---|---|
| What it is | A premarket notification showing the device is substantially equivalent to a legally marketed predicate device. | A premarket approval application establishing, from original evidence, that the device is safe and effective for its intended use. |
| Evidence standard | Substantial equivalence to a predicate — same intended use and equivalent technology, or differences shown not to raise new safety questions. | Valid scientific evidence providing reasonable assurance of safety and effectiveness, judged independently of any predicate. |
| FDA action | The FDA "clears" the device for marketing. | The FDA "approves" the device for marketing. |
| Typical device class | Most Class II (moderate-risk) devices, and some Class I. | Class III (high-risk) devices that support or sustain life or pose potential unreasonable risk. |
| Clinical data | Often not required; many submissions rely on bench and performance testing, though some need clinical data. | Usually required — well-controlled clinical investigations typically support the application. |
| Relative burden | Generally lower cost and shorter timeline, reflecting the comparison-based standard. | Generally higher cost and longer timeline, reflecting the independent evidentiary standard. |
| Governing regulation | Section 510(k) of the FD&C Act; 21 CFR Part 807, Subpart E. | Section 515 of the FD&C Act; 21 CFR Part 814. |
| Advisory panel | Rarely involves an external advisory panel. | May involve an FDA advisory committee of outside experts for novel devices. |
| Post-market change | A significant change may require a new 510(k) submission. | A significant change generally requires a PMA supplement. |
Common questions
FAQ
Is "cleared" the same as "approved" for a medical device?+
No. The FDA "clears" a 510(k) device based on substantial equivalence to a predicate, and "approves" a PMA device based on independent evidence of safety and effectiveness. The wording reflects two different regulatory standards, so the terms are not interchangeable.
Which pathway needs clinical trials?+
A PMA usually requires clinical data — typically well-controlled clinical investigations — because it must independently establish safety and effectiveness. A 510(k) often relies on bench and performance testing against a predicate, though some 510(k) submissions also include clinical data.
How does a device end up on the PMA pathway instead of 510(k)?+
Device class drives the pathway. High-risk Class III devices generally require a PMA, while most moderate-risk Class II devices use 510(k). Novel lower-risk devices without a predicate may instead use the De Novo classification route rather than being forced into a PMA.
Going deeper
